AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02693769
Drug: fluticasone propionate/formoterol fumarate breath actuated inhaler
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02693769
Drug: Indacaterol maleate / glycopyrronium bromide capsules
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02537938
Drug: NGP 555
RxNorm normalized name: avalglucosidase alfa-ngpt
DrugBank: Avalglucosidase alfa (DB16099)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01464229
Drug: Iloperidone
RxNorm normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloperidone 1-8 mg for 4 weeks
Trial: NCT00775736
Drug: biphasic insulin aspart 30
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
Trial: NCT00775736
Drug: biphasic insulin aspart 50
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
Trial: NCT00252317
Drug: Captopril and Trandolapril
RxNorm normalized name: trandolapril and verapamil
DrugBank: Trandolapril (DB00519)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
Trial: NCT00775736
Drug: biphasic insulin aspart 70
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
Trial: NCT00437671
Drug: Tetanus Immune Globulin (Human)
RxNorm normalized name: Tetanus Immune Globulin (Human)
DrugBank: Tetanus immune globulin, human (DB11604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Based on package insert recommendation and recommendations of WHO
Trial: NCT00252317
Drug: Captopril Test Dose and Trandolapril
RxNorm normalized name: trandolapril and verapamil
DrugBank: Trandolapril (DB00519)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
Trial: NCT00980356
Drug: Vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Patients receive once daily 50 mg Vildagliptin
Trial: NCT00051493
Drug: ALIMTA
RxNorm normalized name: Alimta
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00051493
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00531882
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg once a day
Trial: NCT01737138
Drug: medicine
RxNorm normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agent, statins, platelet aggregation inhibitor, anticoagulants and so on.
Trial: NCT01446991
Drug: Degarelix
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 240 mg loading dose followed by monthly 80 mg maintenance dose for 2-3 months
Trial: NCT01446991
Drug: Degarelix
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 240 mg loading dose of Degarelix followed by 80 mg maintenance doses every month for a total duration of 6 months.
Trial: NCT02426463
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02426463
Drug: oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05421962
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ninety patients were included and randomized to either fentanyl-propofol (Group FP, n: 30), ketamine-propofol (Group KP, n: 30) or propofol-control group (Group C, n: 30). Group FP patients received fentanyl and propofol, Group KP received ketamine and propofol and Group C, propofol.
Trial: NCT03196986
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then switched to mil60 at 7.5mg/kg
Trial: NCT00024180
Drug: romidepsin
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01308086
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 \& 2, q2w, for 12 cycles
Trial: NCT01308086
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 12 cycles
Trial: NCT01308086
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 8 cycles
Trial: NCT01308086
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 \& 2, q2w, for 6 cycles
Trial: NCT01308086
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 4 cycles
Trial: NCT01308086
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 6 cycles
Trial: NCT00301223
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03769064
Drug: Methylphenidate 60 mg
RxNorm normalized name: methylphenidate 60 mg/24 hours oral capsule, extended release
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Potential subjects will be screened to determine their eligibility for the study within 28 days of the first dose in the Qualification Phase (i.e., Days -28 to -2). Eligible subjects will be admitted to the clinical site on Day -1 of the Qualification Phase (Part 1) and randomized on Day 1 to receive placebo and MPH (60 mg) in 1 of 2 sequences with a 48-hour washout between dose administrations (i.e., dose administration on Days 1 and 3).
Trial: NCT03769064
Drug: Treatment Phase Sequence 4213
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
Trial: NCT03769064
Drug: Treatment Phase Sequence 2134
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
Trial: NCT03769064
Drug: Treatment Phase Sequence 1342
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
Trial: NCT00900666
Drug: botulinum toxin A (BTX-A)
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 200 Units BTX-A reconstituted with 2 cc sterile normal saline in 100:1 ratio. Teflon-coated EMG guidance for confirmation of injection into the Rectus femoris muscle in addition to utilizing standardized injection landmarks, the solution will be injected in 0.5 cc aliquots into 4 different injectate sites within the muscle.
Trial: NCT00748345
Drug: Caspofungin (drug)
DrugBank: Caspofungin (DB00520)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pharmacokinetics of caspofungin in burn patients after a single usual dose (70 mg i.v.), in order to determine the optimal dose in this population
Trial: NCT03769064
Drug: Treatment Phase Sequence 3421
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
Trial: NCT04272541
Drug: Psychopharmacology intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention program consisted of psychopharmacology. This will be executed during 3 months.
Trial: NCT04307953
Drug: AZD0530 Difumarate
RxNorm normalized name: Emedastine Difumarate
DrugBank: Emedastine (DB01084)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AZD0530 for the duration of the trial
Trial: NCT00541125
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00921570
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: calcium channel blocker (Amlodipine 10 mg) during 12 weeks
Trial: NCT02476890
Drug: Gefapixant 100 mg
RxNorm normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Gefapixant 100 mg (2 x 50 mg tablets), administered orally as a single dose in treatment Period 1 or treatment Period 2
Trial: NCT00921570
Drug: Valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: AII receptor blocker inhibitor (Valsartan 160 mg) during 12 weeks
Trial: NCT02945852
Drug: apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apatinib 500mg/d until progressive Disease
Trial: NCT00194623
Drug: Botulinum Toxin A (Botox)
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Trial: NCT00082810
Drug: fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given intramuscularly
Trial: NCT00082810
Drug: tipifarnib
RxNorm normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00354406
Drug: abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: standard i.v. bolus of abciximab is administered at time of randomization in arm A, and at time of primary angioplasty in arm B.
Trial: NCT00243854
Drug: Tarceva
RxNorm normalized name: Tarceva
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tarceva: 100mg/day x 2 weeks (Days 1-14) +
Trial: NCT03444506
Drug: Molo 1 (also referred as GSP 301-2 NS)
RxNorm normalized name: NS-2
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03444506
Drug: Molo 2 (also referred as GSP 301-1 NS)
RxNorm normalized name: NS-2
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03444506
Drug: PATANASE nasal spray
RxNorm normalized name: olopatadine Metered Dose Nasal Spray [PATANASE]
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03687827
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive insulin degludec U100 subcutaneous (s.c.) injection once daily for 36 weeks. Doses will be adjusted according to the fasting self-measured plasma glucose (SMPG) values. Participants earlier treated with one or more allowed oral antidiabetic drug(s) (OAD(s)), should continue their pre-trial OAD(s) treatment throughout the trial.
Trial: NCT03687827
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive insulin glargine U100 s.c. injection once daily for 36 weeks. Doses will be adjusted according to the fasting SMPG values. Participants earlier treated with one or more allowed OAD(s), should continue their pre-trial OAD(s) treatment throughout the trial.
Trial: NCT00625937
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00625937
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00625937
Drug: tegafur-gimeracil-oteracil potassium
RxNorm normalized name: tegafur
DrugBank: Oteracil (DB03209)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT02485444
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 IU oxytocin in 500 ml normal saline will be infused 100 ml/h i.v. after fetus is delivered
Trial: NCT00509639
Drug: 10% Metronidazole Ointment
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole 10% ointment applied perianally three times daily for four weeks. Placebo ointment applied perianally three times daily for four weeks
Trial: NCT02950558
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single injection of ropivacaine immediately prior to surgery.
Trial: NCT00288691
Drug: Asoprisnil (BAY86-5294)
RxNorm normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg/day
Trial: NCT00288691
Drug: Asoprisnil (BAY86-5294)
RxNorm normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg/day
Trial: NCT01633528
Drug: Asprin
RxNorm normalized name: Easprin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg
Trial: NCT00288691
Drug: Asoprisnil (BAY86-5294)
RxNorm normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg/day
Trial: NCT03385967
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Addition of Dexmedetomidine in block .25mcg/kg of dexmedetomidine
Trial: NCT03385967
Drug: ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of care 0.5%ropivacaine
Trial: NCT01018836
Drug: riluzole
RxNorm normalized name: Riluzole
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The first dose of Riluzole will be day 0 of study enrollment. WBRT must begin within 48 hours of the initiation of Riluzole therapy. At the completion of radiation, Riluzole should be discontinued and steroids should be tapered over the course of 1-3 weeks, at the discretion of the treating physicians.
Trial: NCT02387450
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg per day
Trial: NCT00987727
Drug: carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD)
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop in each eye three to six times daily, as needed
Trial: NCT00987727
Drug: sodium hyaluronate 0.18% (VISMED® Multi)
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One drop in each eye three to six times daily, as needed
Trial: NCT01272232
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide 3.0 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
Trial: NCT01272232
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
Trial: NCT02218645
Drug: Brotizolam
RxNorm normalized name: brotizolam
DrugBank: Brotizolam (DB09017)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00631358
Drug: Maxidex
RxNorm normalized name: Maxidex
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Maxidex (0.1% Dexamethasone) 1 drop in each eye 2 times daily
Trial: NCT02807207
Drug: A: pacritinib
DrugBank: Pacritinib (DB11697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment A
Trial: NCT02807207
Drug: C: moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment C
Trial: NCT00002810
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00040443
Drug: CX516
RxNorm normalized name: CX516
DrugBank: CX516 (DB06247)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01344902
Drug: hexaminolevulinate HCl
RxNorm normalized name: HEXAMINOLEVULINATE HCL
DrugBank: Hexaminolevulinate (DB06261)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg hexaminolevulinate HCl capsule 6 hours before colonoscopy
Trial: NCT04026841
Drug: PD-1 antibody Sintilimab
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in experimental group receive the treatment of PD-1 antibody Sintilimab
Trial: NCT01594229
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab will be given by intravenous infusion for 1 day out of each 28 day cycle.
Trial: NCT01594229
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bendamustine will be given by intravenous infusion for 2 days out of each 28 day cycle.
Trial: NCT02894892
Drug: (A)Bismuth
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02041481
Drug: MEK inhibitor MEK162
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02041481
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02894892
Drug: (B)Bismuth
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03745001
Drug: EHP-101 Liquid single dose
RxNorm normalized name: EHP-102
DrugBank: EHP-102 (DB16933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single oral administration with EHP-101 liquid formulation. The doses will be ascending per cohort from 0.91 mg to 200 mg. The initially planned once daily dose regimen may be modified by the Safety Review Committee based on emerging PK data, eg, assigned dose levels may be divided into 2 doses administered 12 hours apart (twice a day).
Trial: NCT03745001
Drug: EHP-101 Liquid multiple doses
RxNorm normalized name: EHP-102
DrugBank: EHP-102 (DB16933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single daily administration with EHP-101 liquid formulation during 7 consecutive days. The doses will be ascending per cohort. Each ascending level will not exceed the tested dose levels in the single dose part of the study. The initially planned once daily dose regimen may be modified by the Safety Review Committee based on emerging PK data, eg, assigned dose levels may be divided into 2 doses administered 12 hours apart (twice a day)
Trial: NCT04392713
Drug: Ivermectin 6 MG Oral Tablet (2 tablets)
RxNorm normalized name: ivermectin 6 MG
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 mg single dose of Ivermectin will be given to intervention arm
Trial: NCT05398965
Drug: Eucalyptus Oil
RxNorm normalized name: Eucalyptus oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Eucalyptus Oil pack contains Oleum Eucalyptus citriodora, Oleum Eucalyptus globulus, and Peppermint oil, given 4 times daily for 45 minutes each frequency, applied to the mask.
Trial: NCT02894892
Drug: (C)Bismuth
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01789255
Drug: vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01789255
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV or PO
Trial: NCT01789255
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV or PO
Trial: NCT04693312
Drug: Depo medrol
RxNorm normalized name: Depo-Medrol
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: local injection
Trial: NCT00097188
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02894892
Drug: (D)Esomeprazole and Bismuth
RxNorm normalized name: naproxen and esomeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02894892
Drug: (E)Esomeprazole and Bismuth
RxNorm normalized name: naproxen and esomeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02894892
Drug: (F)Esomeprazole and Bismuth
RxNorm normalized name: naproxen and esomeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no